Get 20% Free Customization In This Report

Buy this report from - $3456

Vasculitis Treatment Market by Drug Class (Corticosteroids, Immunosuppressants, and Biologics); Disease Type (Small Vessel and Medium Vessel Vasculitis); and End User (Government, Hospitals, and Medical Clinics) - Global Opportunities and Industry Forecasts, 2017-2023

Diagnostics and Biotech	LI_183523	Pages: NA	Jul 2018 \| 677 Views
Author's : NA	Tables: NA	Charts: NA	Formats*:

Vasculitis is a medical condition where the inflammation of blood vessels takes place that affects the skin, eye, brain, or certain internal organs. The associated symptoms observed include fatigue, weakness, weight loss, muscle pain, congestive heart failure, malaise, and others. Treatment techniques include various medications such as corticosteroids and cytotoxic medicines.

The major factors that contribute to the growth of the vasculitis treatment market include increasing prevalence of chronic diseases due to sedentary lifestyles, rise in geriatric population who are more prone to cardiovascular diseases, high demand for minimally invasive procedures, better healthcare infrastructure, and technological advancements & innovations that lead to intense competition among key players. However, lack of trained professionals and stringent governmental regulations for these drugs restrict the market growth. Recent innovations, which embed the introduction of innovative ideas such as use of sequential magnetic resonance imagingmagnetic resonance angiography (MRIMRA) will provide better results to the physicians and allow them to work more efficiently, thus fostering the market growth.

The global vasculitis treatment market is segmented on the basis of drug class, disease type, end user, and region. Based on drug class, it is divided into corticosteroids, immunosuppressants, and biologics. Based on disease type, the market is categorized into small vessel and medium vessel vasculitis. According to end user, the market is divided into government, hospitals, medical clinics, and others. Geographically, the market has been analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The key players that operate in this market include GlaxoSmithKline plc, F. Hoffmann-La Roche AG, Celgene Corporation, Ablynx, Gilead, Novartis AG, Bristol-Myers Squibb Company, Novo Nordisk A/S, Eli Lilly and Company, and Merck & Co., Inc.

Key Benefits

The study provides an in-depth analysis of the global vasculitis treatment market with current trends and future estimations to elucidate imminent investment pockets.
The report provides information about the current and upcoming trends in the global vasculitis treatment market from 2016 to 2023, which helps determine prevailing opportunities.
Comprehensive analysis of factors that drive and restrict the growth of the global vasculitis treatment market has been provided.
Identification of factors that are instrumental in changing the market scenario, rise in opportunities, and identification of key companies that can influence this market on a global and regional scale have been provided.
Key market players within the market have been profiled in this report and their strategies thoroughly analyzed, which help understand the competitive outlook of the global vasculitis treatment market.

Vasculitis Treatment Market Key Segments:

By Drug Class

Corticosteroids
Immunosuppressants
Biologics

By Disease Type

Small Vessel Vasculitis
Medium Vessel Vasculitis

By End User

Government
Hospitals
Medical Clinics
Others

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- UK
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA

Chapter: 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

Chapter: 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

Chapter: 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. MARKET SHARE ANALYSIS, 2016
3.4. PORTER’S FIVE FORCES ANALYSIS

3.4.1. MARKET DYNAMICS
3.4.2. Drivers
3.4.3. Restraints
3.4.4. Opportunities

Chapter: 4 VASCULITIS TREATMENT MARKET, BY DRUG CLASS

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. CORTICOSTEROIDS

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast

4.3. IMMUNOSUPPRESSANTS

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast

4.4. BIOLOGICS

4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast

Chapter: 5 VASCULITIS TREATMENT MARKET, BY DISEASE TYPE

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. SMALL VESSEL VASCULITIS

5.2.1. Market size and forecast

5.3. MEDIUM VESSEL VASCULITIS

5.3.1. Market size and forecast

Chapter: 6 VASCULITIS TREATMENT MARKET, BY END USER

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. GOVENRMENT

6.2.1. Market size and forecast

6.3. HOSPITALS

6.3.1. Market size and forecast

6.4. MEDICAL CLINICS

6.4.1. Market size and forecast

6.5. OTHERS

6.5.1. Market size and forecast

Chapter: 7 VASCULITIS TREATMENT MARKET, BY REGION

7.1. OVERVIEW
7.2. NORTH AMERICA

7.2.1. Key market trends
7.2.2. Key growth factors and opportunities
7.2.3. Market size and forecast

7.2.3.1. U.S. market size and forecast
7.2.3.2. Canada market size and forecast
7.2.3.3. Mexico market size and forecast

7.2.4. North America vasculitis treatment market by drug class
7.2.5. North America vasculitis treatment market by disease type
7.2.6. North America vasculitis treatment market by end user

7.3. EUROPE

7.3.1. Key market trends
7.3.2. Key growth factors and opportunities
7.3.3. Market size and forecast

7.3.3.1. Germany market size and forecast
7.3.3.2. France market size and forecast
7.3.3.3. UK market size and forecast
7.3.3.4. Italy market size and forecast
7.3.3.5. Spain market size and forecast
7.3.3.6. Rest of Europe market size and forecast

7.3.4. Europe vasculitis treatment market by drug class
7.3.5. Europe vasculitis treatment market by disease type
7.3.6. Europe vasculitis treatment market by end user

7.4. ASIA-PACIFIC

7.4.1. Key market trends
7.4.2. Key growth factors and opportunities
7.4.3. Market size and forecast

7.4.3.1. Japan market size and forecast
7.4.3.2. China market size and forecast
7.4.3.3. Australia market size and forecast
7.4.3.4. India market size and forecast
7.4.3.5. South Korea market size and forecast
7.4.3.6. Taiwan market size and forecast
7.4.3.7. Rest of Asia-Pacific market size and forecast

7.4.4. Asia-Pacific vasculitis treatment market by drug class
7.4.5. Asia-Pacific vasculitis treatment market by disease type
7.4.6. Asia-Pacific vasculitis treatment market by end user

7.5. LAMEA

7.5.1. Key market trends
7.5.2. Key growth factors and opportunities
7.5.3. Market size and forecast

7.5.3.1. Brazil market size and forecast
7.5.3.2. Turkey market size and forecast
7.5.3.3. Saudi Arabia market size and forecast
7.5.3.4. South Africa market size and forecast
7.5.3.5. Rest of LAMEA market size and forecast

7.5.4. LAMEA vasculitis treatment market by drug class
7.5.5. LAMEA vasculitis treatment market by disease type
7.5.6. LAMEA vasculitis treatment market by end user

Chapter: 8 COMPANY PROFILES

8.1. GLAXOSMITHKLINE PLC

8.1.1. Operating business segments
8.1.2. Business performance
8.1.3. Key strategic moves and developments

8.2. F. HOFFMANN-LA ROCHE AG

8.2.1. Operating business segments
8.2.2. Business performance
8.2.3. Key strategic moves and developments

8.3. CELGENE CORPORATION

8.3.1. Operating business segments
8.3.2. Business performance
8.3.3. Key strategic moves and developments

8.4. NOVARTIS AG

8.4.1. Operating business segments
8.4.2. Business performance
8.4.3. Key strategic moves and developments

8.5. GILEAD

8.5.1. Operating business segments
8.5.2. Business performance
8.5.3. Key strategic moves and developments

8.6. BRISTOL-MYERS SQUIBB COMPANY

8.6.1. Operating business segments
8.6.2. Business performance
8.6.3. Key strategic moves and developments

8.7. NOVO NORDISK A/S

8.7.1. Operating business segments
8.7.2. Business performance
8.7.3. Key strategic moves and developments

8.8. ELI LILLY AND COMPANY

8.8.1. Operating business segments
8.8.2. Business performance
8.8.3. Key strategic moves and developments

8.9. MERCK & CO., INC.

8.9.1. Operating business segments
8.9.2. Business performance
8.9.3. Key strategic moves and developments

8.10. ABLYNX

8.10.1. Operating business segments
8.10.2. Business performance
8.10.3. Key strategic moves and developments

With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
Technologically sophisticated and reliable insights through well audited and veracious research methodology
Sovereign research proceeds that present a tangible depiction of marketplace

With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

Patent and regulatory databases for understanding of technical & legal developments
Scientific and technical writings for product information and related preemptions
Regional government and statistical databases for macro analysis
Authentic new articles, web-casts and other related releases for market evaluation
Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast

Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

Validates and improves the data quality and strengthens research proceeds
Further develops analyst team’s market understanding and expertise
Supplies authentic information about market size, share, growth and forecasts

Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

Chief executives and VPs of leading corporations specific to industry
Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)

Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

Shopping Cart is Empty..

Your Shopping Cart Is Empty

Vasculitis Treatment Market by Drug Class (Corticosteroids, Immunosuppressants, and Biologics); Disease Type (Small Vessel and Medium Vessel Vasculitis); and End User (Government, Hospitals, and Medical Clinics) - Global Opportunities and Industry Forecasts, 2017-2023